 Lack efficacy high-dose leucovorin fluorouracil patients advanced pancreatic adenocarcinoma Leucovorin cytotoxicity fluorouracil experimental tumor systems effectiveness patients colon cancer Twenty-two eligible patients advanced pancreatic adenocarcinoma phase II trial days continuous intravenous infusion rapid intravenous injection consecutive days hours initiation leucovorin infusion assessable patients complete partial regressions minor response months patients stable disease months Median survival weeks Toxicity stomatitis patients diarrhea Hospitalization toxicity necessary untreated patients patients median WBC nadir range /microL median platelet nadir range /microL combination leucovorin meaningful therapeutic activity patients adenocarcinoma pancreas moderate severe toxicity standard treatment patients disease